Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

• Drug: PF-05231023
  
  0.5 mg QD IV x 1 day
• Drug: PF-05231023
  
  1.5 mg QD IV x 1 day
• Drug: PF-05231023
  
  5 mg QD IV x 1 day
• Drug: PF-05231023
  
  15 mg QD IV x 1 day
• Drug: PF-05231023
  
  50 mg QD IV x 1 day
• Drug: PF-05231023
  
  100 mg QD IV x 1 day
• Drug: PF-05231023
  
  200 mg QD IV x 1 day
• Other: Placebo
  
  0.9% w/v sodium chloride injection, USP QD IVx 1 day

• Experimental: Treatment
  
  Interventions:
  

  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
  • Drug: PF-05231023
• Placebo Comparator: Placebo
  
  0.9% w/v sodium chloride injection, USP
  Intervention: Other: Placebo

Inclusion Criteria:

• Male and female subjects between the ages of 30 and 65 years, inclusive, with a historical diagnosis of type 2 diabetes mellitus, diagnosed according to the American Diabetes Association guidelines.
• Body Mass Index (BMI) of 25 to 35.5 kg/m2, and a total body weight >50 kg (110 lbs).
• HbA1c >7% and not to exceed 10.5%.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Diagnosis of Type 1 diabetes mellitus
• Evidence of diabetic complications with significant end organ damage.